CenturyLink Investment Management Co lowered its position in Amgen, Inc. (NASDAQ:AMGN) by 4.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,540 shares of the medical research company’s stock after selling 539 shares during the quarter. Amgen makes up approximately 0.9% of CenturyLink Investment Management Co’s portfolio, making the stock its 24th biggest position. CenturyLink Investment Management Co’s holdings in Amgen were worth $2,192,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund raised its stake in shares of Amgen by 20,103.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after purchasing an additional 31,268,677 shares during the last quarter. Norges Bank purchased a new stake in shares of Amgen during the fourth quarter worth approximately $1,283,248,000. BlackRock Inc. raised its stake in shares of Amgen by 2.0% during the fourth quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock worth $8,979,621,000 after purchasing an additional 906,568 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Amgen by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after purchasing an additional 482,760 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in shares of Amgen by 536.5% during the fourth quarter. Epoch Investment Partners Inc. now owns 524,376 shares of the medical research company’s stock worth $102,080,000 after purchasing an additional 441,995 shares during the last quarter. Institutional investors own 80.00% of the company’s stock.
Shares of AMGN stock opened at $176.50 on Friday. Amgen, Inc. has a 1-year low of $165.22 and a 1-year high of $210.19. The firm has a market cap of $110.45 billion, a P/E ratio of 12.26, a price-to-earnings-growth ratio of 2.20 and a beta of 1.15. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.11. The firm had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.55 billion. Amgen had a return on equity of 67.08% and a net margin of 34.00%. Amgen’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.47 earnings per share. Equities analysts predict that Amgen, Inc. will post 13.95 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 annualized dividend and a yield of 3.29%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 40.28%.
Several research firms have recently commented on AMGN. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a research note on Sunday, January 27th. Mizuho restated a “buy” rating and set a $211.00 price target on shares of Amgen in a research note on Tuesday, February 26th. BidaskClub cut Amgen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Citigroup upped their price target on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research note on Friday, January 4th. Finally, Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. Amgen currently has an average rating of “Hold” and an average price target of $208.84.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the sale, the director now owns 15,092 shares of the company’s stock, valued at $2,915,472.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Insiders sold 6,000 shares of company stock worth $1,144,120 in the last three months. 0.25% of the stock is owned by corporate insiders.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: What are retained earnings?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN). Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN) Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at CenturyLink Investment Management Co Trims Holdings in Amgen, Inc. (AMGN)